Regulatory T-cells in B-cell chronic lymphocytic leukemia: Their role in disease progression and autoimmune cytopenias

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 1012-1019

  Lad, Deepesh P ^a   Varma, Subhash ^a   Varma, Neelam ^a   Sachdeva, Man Updesh Singh ^a   Bose, Parveen ^a   Malhotra, Pankaj ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Autoimmune cytopenia; Chronic lymphocytic leukemia; Lymphocyte doubling time; Regulatory T cells

Indexed keywords

INTERLEUKIN 7 RECEPTOR; PROTEIN KINASE ZAP 70; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B CELL LEUKEMIA; BONE MARROW EXAMINATION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; COOMBS TEST; CYTOPENIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN SIZE; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; AUTOIMMUNITY; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84876241418     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.728287     Document Type: Article

References (28)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Croci DO, Zakaria FM, Rico MJ, et al. Dynamic cross talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56:1687-1700.
3. Sakaguchi S, Wing K, Miyara M. Regulatory T cells- A brief history and perspective, Eur J Immunol 2007;37:S116-S123.
4. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-2025.
5. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-682.
6. Deutsch V, Perry C, Polliack A. Expansion of regulatory T cells in B cell CLL. Enhanced brakes on host immunity. Leuk Lymphoma 2009;50:788-801.
7. Biancotto A, Fuchs JC, Dagur P, et al. Characterization of Treg subpopulations in CLL using 15 color fow cytometry. Blood 2009; 114(Suppl. 1): Abstract 1644.
8. D Arena G, Laurenti L, Minervini M, et al. Regulatory T cell number is increased in CLL patients and correlates with progressive disease. Leuk Res 2011;35:363-368.
9. Beyer M, Schultze J. Regulatory T cells in cancer. Blood 2006; 108:804-11.
10. Lindquist CA, Christiansson LH, Mangsbo S, et al. FOXP3 T-cells in patients with B-cell CLL express cytolytic markers and kill autologous B cells. Immunology 2011;133:296-306.
11. Zhao DM, Tornton AM, DiPaolo RJ, et al. Activated CD4+CD25 + T cells selectively kill B lymphocytes. Blood 2006; 107: 3925-3932.
12. Alvaro T, Lejeune M, Esciva P, et al. Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit Rev Oncol Hematol 2009;70:103-113.
13. Baecher-Allan C, Haffer DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006; 212: 203-216.
14. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol 2009;16:274-279.
15. La Cava A. Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 2008; 8: 83-87.
16. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
17. Varma S, Lad D, Varma N, et al. Do regulatory T cells have a role in disease progression and autoimmune cytopenias of chronic lymphocytic leukemia? Blood 2011; 118(Suppl. 1): Abstract 3864.
18. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203:1701-1711.
19. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788-801.
20. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008;111:5446-5456.
21. Shevach EM. Mechanisms of Foxp3 Treg cell mediated suppression. Immunity 2009;30:636-645.
22. Waldmann H, Cobbold S. Regulatory T cells: context matters. Immunity 2009;5:613-615.
23. Molica S, Alberti A. Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712-2716.
24. Zent CS, Ding W, Reinalda MS, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 2009; 50:1261-1268.
25. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector T17 and regulatory T cells. J Clin Immunol 2008;28:660-670.
26. Marti G, Orfao A, Goolsby C. ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue. Cytometry B Clin Cytom 2006; 70: 197-200.
27. Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011;117:2163-2169.
28. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-887.